Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3.

McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2356-63. doi: 10.2215/CJN.02420311.

2.

Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease.

Smit AJ, Gerrits EG.

Curr Opin Nephrol Hypertens. 2010 Nov;19(6):527-33. doi: 10.1097/MNH.0b013e32833e9259. Review.

PMID:
20844429
3.

Skin autofluorescence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease.

de Vos LC, Noordzij MJ, Mulder DJ, Smit AJ, Lutgers HL, Dullaart RP, Kamphuisen PW, Zeebregts CJ, Lefrandt JD.

Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):131-8. doi: 10.1161/ATVBAHA.112.300016.

4.

Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients.

Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ.

J Am Soc Nephrol. 2005 Dec;16(12):3687-93.

5.

Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients.

Oleniuc M, Schiller A, Secara I, Onofriescu M, Hogas S, Apetrii M, Siriopol D, Covic A.

Int Urol Nephrol. 2012 Oct;44(5):1441-9. doi: 10.1007/s11255-011-0097-5.

PMID:
22160646
6.

Influence of age and measure of eGFR on the association between renal function and cardiovascular events.

van der Velde M, Bakker SJ, de Jong PE, Gansevoort RT.

Clin J Am Soc Nephrol. 2010 Nov;5(11):2053-9. doi: 10.2215/CJN.08851209.

7.

Skin autofluorescence is associated with the progression of chronic kidney disease: a prospective observational study.

Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y, Kusano Y, Suzuki H, Hayashi Y, Asahi K, Sato K, Miyata T, Watanabe T.

PLoS One. 2013 Dec 12;8(12):e83799. doi: 10.1371/journal.pone.0083799.

8.

Tissue advanced glycation end product deposition after kidney transplantation.

Crowley LE, Johnson CP, McIntyre N, Fluck RJ, McIntyre CW, Taal MW, Leung JC.

Nephron Clin Pract. 2013;124(1-2):54-9. doi: 10.1159/000355692.

PMID:
24135496
9.

Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients.

Tanaka K, Tani Y, Asai J, Nemoto F, Kusano Y, Suzuki H, Hayashi Y, Asahi K, Katoh T, Miyata T, Watanabe T.

Nephrol Dial Transplant. 2011 Jan;26(1):214-20. doi: 10.1093/ndt/gfq369.

PMID:
20591816
10.

The impact of antihypertensive drug therapy on endotoxemia in elderly patients with chronic kidney disease.

John SG, Owen PJ, Harrison LE, Szeto CC, Lai KB, Li PK, McIntyre CW.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2389-94. doi: 10.2215/CJN.11211210.

11.

Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients.

Hartog JW, de Vries AP, Bakker SJ, Graaff R, van Son WJ, van der Heide JJ, Gans RO, Wolffenbuttel BH, de Jong PE, Smit AJ.

Nephrol Dial Transplant. 2006 Aug;21(8):2263-9.

PMID:
16597636
12.

Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation.

Chitalia N, Raja RB, Bhandara T, Agrawal P, Kaski JC, Jha V, Banerjee D.

J Nephrol. 2010 Jan-Feb;23(1):77-84.

PMID:
20091490
13.

Skin autofluorescence and all-cause mortality in stage 3 CKD.

Fraser SD, Roderick PJ, McIntyre NJ, Harris S, McIntyre CW, Fluck RJ, Taal MW.

Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1361-8. doi: 10.2215/CJN.09510913.

14.

Clinical outcomes in patients with chronic kidney disease: a 5-year retrospective cohort study at a University Hospital in Japan.

Yamashita T, Yoshida T, Ogawa T, Tsuchiya K, Nitta K.

Clin Exp Nephrol. 2011 Dec;15(6):831-40. doi: 10.1007/s10157-011-0501-6.

PMID:
21800234
15.

Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease.

Makulska I, Szczepańska M, Drożdż D, Polak-Jonkisz D, Zwolińska D.

Pediatr Nephrol. 2013 Jan;28(1):121-8. doi: 10.1007/s00467-012-2280-z.

16.

Autofluorescence of Skin Advanced Glycation End Products: Marker of Metabolic Memory in Elderly Population.

Rajaobelina K, Cougnard-Gregoire A, Delcourt C, Gin H, Barberger-Gateau P, Rigalleau V.

J Gerontol A Biol Sci Med Sci. 2015 Jul;70(7):841-6. doi: 10.1093/gerona/glu243.

PMID:
25589479
17.

Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.

Ravera M, Noberasco G, Re M, Filippi A, Gallina AM, Weiss U, Cannavò R, Ravera G, Cricelli C, Deferrari G.

Nephrol Dial Transplant. 2009 May;24(5):1528-33. doi: 10.1093/ndt/gfn692.

PMID:
19073656
18.

Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study.

Noordzij MJ, Mulder DJ, Oomen PH, Brouwer T, Jager J, Castro Cabezas M, Lefrandt JD, Smit AJ.

Diabet Med. 2012 Dec;29(12):1556-61. doi: 10.1111/dme.12005.

PMID:
22937960
19.

Determinants of arterial stiffness in chronic kidney disease stage 3.

McIntyre NJ, Fluck RJ, McIntyre CW, Fakis A, Taal MW.

PLoS One. 2013;8(1):e55444. doi: 10.1371/journal.pone.0055444.

20.

Urinary cystatin C as a potential risk marker for cardiovascular disease and chronic kidney disease in patients with obesity and metabolic syndrome.

Satoh-Asahara N, Suganami T, Majima T, Kotani K, Kato Y, Araki R, Koyama K, Okajima T, Tanabe M, Oishi M, Himeno A, Kono S, Sugawara A, Hattori M, Ogawa Y, Shimatsu A; Japan Obesity and Metabolic Syndrome Study (JOMS) Group..

Clin J Am Soc Nephrol. 2011 Feb;6(2):265-73. doi: 10.2215/CJN.04830610.

Items per page

Supplemental Content

Support Center